A Retrospective Assessment of Novel Biomarkers Indicating Intestinal Inflammation and Intestinal Permeability, Identified During Non-Invasive Leaky Gut Testing
A Retrospective Assessment of Novel Biomarkers Indicating Intestinal Inflammation and Intestinal Permeability, Identified During Non-Invasive Leaky Gut Testing
-
Clinical Trial Information
Trial Contact: Winbigler, Holly M; Wills, Caitlin C
Trial Phone: 321.841.3938 ; 3218419560
-
IRB No: 24.034.02
Protocol Abbrev: Retro Leaky Gut Biomarkers
Principal Investigator: Vijay Mehta, DO
Age Group: Pediatric
-
Objective
Measure metabolites, I-FABP and other TJ proteins in urine samples that were collected for non-invasive leaky gut testing
Compare levels of I-FABP and TJ proteins between different disease states. -
Key Eligibility
Patients who were diagnosed with Type 1 Diabetes Mellitus (T1DM), celiac disease,
(CD) T1DM and CD, small intestinal microbial overgrowth (SIMO), IBD (Inflammatory
bowel disease), FAPS ( Functional abdominal pain syndrome) and healthy controls.
Patients from the pediatric gastroenterology clinic and endocrinology that previously
underwent leaky gut as part of a study or clinical evaluation between 1/1/2014 to
4/23/2024.
